Search for content, post, videos

Targovax completes enrollment in its ONCOS-102 trial

Magnus Jäderberg
Targovax has completed patient enrollment in the phase I trial with ONCOS-102 in combination with Keytruda in patients with advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma. In this trial, ONCOS-102 immune activation is being tested in patients with advanced, unresectable melanoma
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.